NephrosNEPH +0.89%63 Shareholder Yield % is 0.94% as of Mar. 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.88 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 819 Medical Devices & Instruments companies, Nephros ranks better than 59.22% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Nephros's Shareholder Yield % was 0.94%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Nephros Shareholder Yield % Related Terms
Nephros Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Nephros's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEPH vs MLSS, RGNT, HBIO: Shareholder Yield % Comparison
For the Medical Instruments & Supplies subindustry, Nephros's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros Shareholder Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Nephros's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Nephros (NEPH) has a Shareholder Yield % of 0.94% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Nephros and its competitors. According to the industry distribution chart, Nephros ranks #334 out of 819 companies in the Medical Devices & Instruments industry, placing it in the top 40.8%.
Is Nephros' Shareholder Yield % too high?
Nephros' current Shareholder Yield % is 0.94%. The Medical Devices & Instruments industry median Shareholder Yield % is 0.17. Nephros' value of 0.94% is 452.9% above this industry median. Based on the distribution chart, Nephros ranks #334 out of 819 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Shareholder Yield % compare to MLSS and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #334 out of 819 companies for Shareholder Yield %. This puts Nephros in the upper half of its industry. The industry median Shareholder Yield % is 0.17. Nephros' value of 0.94% is 452.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.17, based on 819 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephros's current Shareholder Yield % of 0.94% is 452.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Nephros and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current Shareholder Yield % is 0.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.88, compared to a current price of $3.40 — trading 18.1% above its estimated fair value. The current Shareholder Yield % is 0.94% and 452.9% above the Medical Devices & Instruments industry median of 0.17. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Nephros (NEPH), the current Shareholder Yield % is 0.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $3.40 is trading 18.1% above its estimated GF Value™ of $2.88.
GuruFocus considers Nephros to be Modestly Overvalued.
Key valuation signals for NEPH:
Shareholder Yield %: 0.94%
GF Value™: $2.88 vs. price of $3.40 (18.1% above fair value)
Industry Position: 452.9% above the Medical Devices & Instruments median (#334 of 819)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score
Get the complete analysis for NEPH
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
